

Thames Valley Priorities Committee Commissioning Policy Statement

Policy No 291 (TVPC79) Iron Chelation in Myelodysplastic Syndrome (MDS)

**Recommendation made by
the Priorities Committee:** September 2018

Date agreed by OCCG 6th December 2018

Date of issue: **December 2018**

The use of iron chelating drugs in the management of Myelodysplastic Syndrome (MDS) will be funded, after a decision to recommend treatment by the multidisciplinary team (MDT), for the following groups:

- Patients on a regular red cell transfusion programme who have a prognosis of greater than 2 years (IPSS-R score of 3.0 or less).
- Patients who are transplant eligible with high risk forms of MDS as defined by the MDT.

This policy is in line with Thames Valley Strategic Clinical Network guidelines ¹

¹ Thames Valley Strategic Clinical Network (2017): Oral Iron Chelation in MDS
<http://nssg.oxford-haematology.org.uk/myeloid/guidelines/ML-25-guidelines-for-oral-iron-chelation-in-mds.pdf>

NOTES:

- Potentially exceptional circumstances may be considered by a patient's CCG where there is evidence of significant health status impairment (e.g. inability to perform activities of daily living) and there is evidence that the intervention sought would improve the individual's health status.
- This policy will be reviewed in the light of new evidence or new national guidance, e.g., from NICE.
- Thames Valley clinical policies can be viewed at <http://www.fundingrequests.ccsu.nhs.uk/>
- Oxfordshire CCG clinical policies can be viewed at <http://www.oxfordshireccg.nhs.uk/professional-resources/policies>